These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

344 related items for PubMed ID: 18554199

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Flecainide therapy suppresses exercise-induced ventricular arrhythmias in patients with CASQ2-associated catecholaminergic polymorphic ventricular tachycardia.
    Khoury A, Marai I, Suleiman M, Blich M, Lorber A, Gepstein L, Boulos M.
    Heart Rhythm; 2013 Nov; 10(11):1671-5. PubMed ID: 23954267
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Importance of ventricular tachycardia storms not terminated by implantable cardioverter defibrillators shocks in patients with CASQ2 associated catecholaminergic polymorphic ventricular tachycardia.
    Marai I, Khoury A, Suleiman M, Gepstein L, Blich M, Lorber A, Boulos M.
    Am J Cardiol; 2012 Jul 01; 110(1):72-6. PubMed ID: 22481011
    [Abstract] [Full Text] [Related]

  • 12. Noninvasive risk stratification prevents sudden death due to paroxysmal atrial fibrillation in hypertrophic cardiomyopathy.
    Limongelli G, Elliott PM, Pacileo G, Sarubbi B, Thaman R, Calabrò P, Vergara P, Iacomino M, Russo MG, Calabrò R.
    J Cardiovasc Med (Hagerstown); 2006 Sep 01; 7(9):711-3. PubMed ID: 16932087
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Catecholaminergic polymorphic ventricular tachycardia.
    Liu N, Colombi B, Raytcheva-Buono EV, Bloise R, Priori SG.
    Herz; 2007 May 01; 32(3):212-7. PubMed ID: 17497254
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Device complications and inappropriate implantable cardioverter defibrillator shocks in patients with hypertrophic cardiomyopathy.
    Lin G, Nishimura RA, Gersh BJ, Phil D, Ommen SR, Ackerman MJ, Brady PA.
    Heart; 2009 May 01; 95(9):709-14. PubMed ID: 19282314
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Catecholaminergic polymorphic ventricular tachycardia: a current overview.
    Leite LR, Henz BD, Macedo PG, Santos SN, Barreto JR, Zanatta A, Fenelon G, Cruz Filho FE.
    Future Cardiol; 2009 Mar 01; 5(2):191-9. PubMed ID: 19371192
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.